good things happening here...tip of the iceberg.
grabbed some more at $3.05...it's gonna run Mon, and throughout next week with ASCO imo.
the shorts will try to take it down, but Monday imo will be even better for investors who got in around the $3 range today. watch the volume on the dips, and $3 brings institutional interest. see you in the mid-$4's on Mon!!
imo, we'll see north of $4 by Mon pm...close.
see you guys just south of $5 next week. have a great weekend!!!
anticipation of ASCO, then the REAL media circus begins!
exposure, exposure, EXPOSURE!!!
should've held for $4...but you made a profit; can't argue with your rationale for selling. imo, ONTY waaaaayyy undervalued compared to other breast cancer biopharma. good luck wherever the market takes you.
Oncothyreon Inc. (NASDAQ: ONTY) has two abstracts related to ONT-380 for the treatment of breast cancer published for ASCO. One of the abstracts summarized data from a triplet therapy that consisted of Oncothyreon’s experimental ONT-380. At the same time, ONT-380 was combined with Xeloda and Herceptin in patients with heavily pre-treated HER2-positive breast cancer.
for me, XXII was a "social consciousness" play, and the long-term is sunny imo. will wait for news re: expansion into China, Japan, etc., where smoking (and efforts to quit) are even more robust than here in the USA. Good luck.
companies in this space should excel, but ONTY has immediate opportunity with ASCO...imo
with his latest claims, this one will not recover quickly...imo. XXII is the next mover, imo.